Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.8K Sell
29
-9
-24% -$1.15K ﹤0.01% 2794
2026
Q2
$7.2K Sell
38
-6
-14% -$890 ﹤0.01% 2527
2026
Q1
$4.1K Hold
44
– – ﹤0.01% 2383
2025
Q4
$3.54K Sell
44
-11
-20% -$921 ﹤0.01% 2463
2025
Q3
$5.37K Buy
55
+26
+90% +$2.09K ﹤0.01% 2172
2025
Q2
$2.02K Hold
29
– – ﹤0.01% 2304
2025
Q1
$1.44K Sell
29
-9
-24% -$569 ﹤0.01% 2373
2024
Q4
$2.66K Sell
38
-29
-43% -$2.41K ﹤0.01% 2210
2024
Q3
$7.02K Buy
+67
New +$7.84K ﹤0.01% 1884

Other funds holding ACLS

BFC Planning's ACLS Position: Q3 2026 in Review

BFC Planning reduced its Axcelis (ACLS) stake by 24% in Q3 2026, selling an estimated $1.15K and leaving 29 shares worth $3.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2794.

BFC Planning first reported a position in ACLS in Q3 2024 and has held it in 9 quarters since. The position peaked at $7.2K in Q2 2026. 304 funds tracked by Wall St. Rank hold ACLS as of Q3 2026.

  • BFC Planning held 29 shares of Axcelis worth $3.8K as of Q3 2026.
  • BFC Planning sold 9 Axcelis shares in Q3 2026, an estimated $1.15K.
  • Axcelis made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2794 holding.
  • BFC Planning first reported a position in Axcelis in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Axcelis position peaked at $7.2K in Q2 2026.
  • 304 funds tracked by Wall St. Rank held Axcelis as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.